Cargando…

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion

Detalles Bibliográficos
Autores principales:	Kurozumi, Kazuhiko, Fujii, Kentaro, Washio, Kana, Ishida, Joji, Otani, Yoshihiro, Sudo, Tamotsu, Tahara, Makoto, Ichimura, Koichi, Ennishi, Daisuke, Date, Isao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268733/ https://www.ncbi.nlm.nih.gov/pubmed/35821677 http://dx.doi.org/10.1093/noajnl/vdac094

Ejemplares similares

Combination of the tubular retractor and brain spatulas provides an adequate operative field in surgery for deep-seated lesions: Case series and technical note
por: Otani, Yoshihiro, et al.
Publicado: (2018)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Integrin Inhibitor Suppresses Bevacizumab-Induced Glioma Invasion()()
por: Ishida, Joji, et al.
Publicado: (2014)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Phenotypic Transition as a Survival Strategy of Glioma
por: ICHIKAWA, Tomotsugu, et al.
Publicado: (2016)

The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib
por: Papusha, Ludmila, et al.
Publicado: (2021)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
por: Grogan, Patrick T, et al.
Publicado: (2022)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
por: Farago, Anna F., et al.
Publicado: (2015)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration
por: Uneda, Atsuhito, et al.
Publicado: (2021)

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
por: Alvarez-Breckenridge, Christopher, et al.
Publicado: (2017)

Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report
por: Tadipatri, Ramya, et al.
Publicado: (2022)

Gene expression profiling of the anti-glioma effect of Cilengitide
por: Onishi, Manabu, et al.
Publicado: (2013)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
por: Ardini, Elena, et al.
Publicado: (2020)

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy
por: MIZUTA, Ryo, et al.
Publicado: (2022)

Neurosurgery for brain metastasis from breast cancer
por: Tomita, Yusuke, et al.
Publicado: (2020)

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion
por: Beck, Olivia G., et al.
Publicado: (2023)

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer
por: Moriyama, Etsuko, et al.
Publicado: (2023)

IDH-mutant Astrocytoma Arising in the Brainstem with Symptom Improvement by Foramen Magnum Decompression: A Case Report
por: NAGASE, Takayuki, et al.
Publicado: (2023)

A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy
por: Oka, Tetsuo, et al.
Publicado: (2016)

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1‐rearranged tumor cells
por: Suzuki, Chiaki, et al.
Publicado: (2022)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
por: Mayr, Lisa, et al.
Publicado: (2020)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
por: Desai, Ami V, et al.
Publicado: (2022)

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
por: Lazzari, Chiara, et al.
Publicado: (2022)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report
por: Dawood, Shaheenah, et al.
Publicado: (2023)

PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma
por: Otani, Yoshihiro, et al.
Publicado: (2017)

Annexin A2–STAT3–Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma
por: Matsumoto, Yuji, et al.
Publicado: (2020)

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
por: Dziadziuszko, Rafal, et al.
Publicado: (2022)

RARE-32. PEDIATRIC METASTATIC SKULL BASE CHORDOMA WITH TP53 MUTATION – A CASE REPORT AND REVIEW OF THE LITERATURE
por: Shimada, Akira, et al.
Publicado: (2020)

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

SURG-21. ENDO- AND EXOSCOPIC SURGERY FOR PEDIATRIC NEUROSURGICAL OPERATION
por: Kurozumi, Kazuhiko, et al.
Publicado: (2020)

Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis
por: Hattori, Yasuhiko, et al.
Publicado: (2022)

Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
por: Onishi, Manabu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cdosns0hd897q5ilkfsb40uu5v